Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : J&J vaccine problems hamper US military vaccines overseas

04/08/2021 | 04:44pm EDT

WASHINGTON (AP) — U.S. military leaders said Thursday that recent problems with the Johnson & Johnson vaccine have made it more difficult to provide shots for forces overseas, and that vaccines have been offered to service members' families or other tier two beneficiaries in only 40% of the military sites outside the U.S.

Speaking at a Pentagon press conference, they said they are making up for the Johnson & Johnson shortfall by shipping more Moderna vaccines to forces outside the country. The cold temperature and other requirements for the Pfizer vaccine make it more difficult to send overseas.

Johnson & Johnson had to discard 15 million doses of its coronavirus vaccine last month because the batch did not met quality standards. The loss in expected vaccines was a greater problem for the military, because it had targeted the Johnson & Johnson shot for distribution overseas since it only requires one dose and doesn’t need the strict temperature controls that others do.

Army Lt. Gen. Ronald J. Place, director of the Defense Health Agency, told reporters that based on President Joe Biden's latest guidance for all adults, the department will begin offering vaccines to all eligible troops, family members and other beneficiaries by April 19.

Some troops and their famlies overseas have expressed frustration at their inability to get a vaccine, particularly since many are in areas, including around Europe, that have been hard hit by the COVID-19 pandemic. Place said that in many locations the vaccines are still being offered only to tier one individuals, which include troops who are deployed, health care or emergency workers, and beneficiaries who are 65 and older.

He added that while just 7% of the eligible Defense Department population is outside the U.S., the Pentagon is shipping 14 percent of the doses it gets to overseas locations.

“That said, if you’re a service member stationed overseas or a family member, likewise stationed overseas, and you haven’t received a vaccine and you don’t know when you’ll be able to, these numbers mean nothing,” said Place. “And it’s understandably frustrating.”

Place said that he expects to be able to deliver at least an initial dose to every eligible Defense Department person overseas who wants one by the middle of May.

Military officials from across the services said that they are seeing an increase in the rate of those agreeing to take the vaccine.

In mid-February, military officials said that thousands of service members were refusing or putting off the COVID-19 vaccine, prompting Defense leaders to beef up efforts to educate troops about the shots, which are strictly voluntary.

Over time, however, Place said that the acceptance rate is growing, althought the Pentagon has not provided numbers and has said it doesn't collect data on those who opt out of the vaccine.

“We continue to see many individuals who were taking a wait and see approach now coming in for the vaccine,” he said.

National Guard leaders said Thursday that close to 18 percent of their forces - or more thanh 76,000 — have been fully vaccinated, and another 111,000 have gotten at least one shot. Guard troops are also working in many states to help deliver the vaccine, particularly in more remote or underserved locations.

There are more than 2,200 guard members spread across 1,000 different sites, including mobile vaccination centers, who are providing vaccines. As of this week, Guard members had administered 6 million shots to people around the country.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about JOHNSON & JOHNSON
04:49pCLOSE UPDATE : US Stocks End Higher Following Two-Day Tumble
MT
04:01pTHE LATEST : New study shows COVID vaccines effective
AQ
03:54pJOHNSON & JOHNSONá : FDA inspection found problems at factory making J&J vaccine
AQ
03:38pJOHNSON & JOHNSONá : FDA Observes Cross-Contamination, Unsanitary Condition at J..
MT
02:40pJOHNSON & JOHNSONá : US FDA Flags Unsanitary Conditions At Emergent BioSolutions
MT
02:09pJOHNSON & JOHNSONá : What We're Reading This Week
AQ
01:35pFDA says Emergent failed to train workers to safely make J&J COVID-19 vaccine
AQ
12:28pEuropean Stocks End Higher as Countries Look to Resume Johnson & Johnson Vacc..
MT
12:27pJOHNSON & JOHNSONá : Europe lines up more shots, hoping to beat back virus surge
AQ
10:58aJOHNSON & JOHNSONá : Germany, Netherlands, Italy to Resume Rollout of Johnson & ..
MT
More news
Financials (USD)
Sales 2021 92 816 M - -
Net income 2021 21 226 M - -
Net cash 2021 1 715 M - -
P/E ratio 2021 20,1x
Yield 2021 2,51%
Capitalization 438 B 438 B -
EV / Sales 2021 4,70x
EV / Sales 2022 4,37x
Nbr of Employees 134 500
Free-Float 83,5%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 182,63 $
Last Close Price 166,48 $
Spread / Highest target 22,5%
Spread / Average Target 9,70%
Spread / Lowest Target -8,10%
EPS Revisions
Managers and Directors
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.78%438 293
ROCHE HOLDING AG-0.31%290 135
PFIZER, INC.5.76%217 716
MERCK & CO., INC.-3.95%198 884
NOVARTIS AG-3.95%198 172
ABBVIE INC.1.75%192 419